Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

NCT ID: NCT05840835

Last Updated: 2023-08-08

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-03
• Study Completion Date: 2024-01-24

Brief Summary

Phase 1/2a Phase 1 is an open-label, multicenter dose escalation/dose expansion study designed to assess the safety, tolerability, pharmacokinetics (PK) and antitumor activity of IMX-110 in combination with Tislelizumab. The recommended Phase 2 dose (RP2D) will be evaluated in further dose expansion Phase 2a study submitted as an amendment to this Phase 1 protocol during the conduct of the Phase 1 study.

Conditions

Advanced Solid Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

IMX-110 in Combination With Tislelizumab

Patients with advanced solid tumors will be administered a combination of IMX-110 with Tislelizumab

Group Type: EXPERIMENTAL

IMX-110 combined with Tislelizumab

Intervention Type: DRUG

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Interventions

IMX-110 combined with Tislelizumab

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Intervention Type: DRUG

Other Intervention Names

One Arm

Eligibility Criteria

Inclusion Criteria

• Male or female patients who are 16 years or older
• Patients with confirmed advanced solid tumor as per histology, who have progressed, are refractory, or are intolerant to standard therapy appropriate for tumor type
• Patients with an Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2 (Appendix 2)
• Patients with a life expectancy of at least 3 months
• Patients with adequate cardiac function as measured by left ventricular ejection fraction >50%
• Patients who have not reached a cumulative total lifetime maximum dose of 550 mg/m2 doxorubicin or per investigator discretion
• Patients who meet the following laboratory requirements:
• Absolute neutrophil count (ANC) ≥ 1.0 x 109/L
• Hemoglobin (HGB) ≥ 9.0 g/dL (patients may be transfused to achieve this HGB level)
• Platelet count ≥ 100 x 109/L
• Total bilirubin level ≤ 1.5 x ULN, or ≤ 3.0 x ULN for patients with Gilbert syndrome
• AST and ALT ≤ 2.5 x ULN (≤5 x ULN if liver metastasis present)
• Creatinine ≤ 1.5 x ULN (Creatinine clearance >50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal) (Creatinine clearance will be measured based on Cockcroft-Gault Equation).
• Women of childbearing potential and men must agree to sexual abstinence or to use highly effective, double barrier contraception during the study and for 6 weeks following the final dose of IMX-110. Double barrier contraception is defined as a condom AND one other form of the following:
• Birth control pills (The Pill)
• Depot or injectable birth control
• IUD (Intrauterine Device)
• Birth control patch (e.g. Ortho Evra)
• NuvaRing®
• Documented evidence of surgical sterilization at least 6 months prior to the screening visit, i.e., tubal ligation or hysterectomy for women or vasectomy for men.

Male patients must not donate sperm for at least 24 weeks post-dose of the last study treatment.

Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1.

Rhythm methods during the study and for 4 months after the dose of IMX-110 + Tislelizumab will not be acceptable.

Exclusion Criteria

• Patients with a history of severe allergic reactions to any unknown allergens or any components of the study drug formulation.
• Patients receiving any chemotherapy within 14 days of dosing, immunotherapy within 28 days of dosing, or biologic or hormonal therapy within 28 days of dosing for cancer treatment (exclusively). Patients with prostate cancer can continue administration of Gonadotropin-releasing hormone (GnRH) agonists.
• Subject participating in any other drug study ≤ 4 weeks (6 weeks for immunotherapy investigational agents) or 5 half-lives of the investigational product, whichever is longer, prior to study drug administration or is scheduled to receive one during the treatment or post-treatment period.
• Patients who are expected to need surgery or benefit from other anti-cancer therapy to be initiated during the study period.
• Patients with a history of and/or risk factors for ischemic heart disease, congestive heart failure, symptomatic bradycardia, atrioventricular (AV) block of second degree or higher grade, prolonged QTcF interval (>450 msec in men and >470 msec in women and additional risk factors for QT prolongation (e.g. hyperthyroidism, electrolyte imbalance). (Pacemaker is not prohibited).
• Patients who have not recovered from adverse events (AEs; ≥ CTCAE grade 2) due to prior treatment (i.e. chemotherapy, targeted therapy, radiation, or surgery) within 7 days prior to Cycle 1 Day 1, unless deemed to be irreversible, or approved by the Sponsor and Medical Monitor.
• Females who are pregnant or lactating or intend to become pregnant before, during, or within 24 weeks after participating in this study; or intending to donate ova during such time period.
• Patients with a known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C antibodies (HCV). Patients may be enrolled if they have HBV, HCVor HIV with viral load suppressed by anti-virals.

Any condition that, in the opinion of the investigator or sponsor, would interfere with evaluation of the investigational product.

• Active autoimmune diseases or history of autoimmune diseases that may relapse or history of life-threatening toxicity related to prior immune therapy. Note: Patients with the following diseases are not excluded and may proceed to further screening:
• Controlled type I diabetes (insulin dependent)
• Hypothyroidism (provided it is managed with hormone replacement therapy only)
• Controlled celiac disease
• Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia)
• Any other disease that is not expected to recur in the absence of external triggering factors (requires consultation with the medical monitor prior to enrollment)
• Indicated live vaccines should be given ≥4 weeks prior to enrollment

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BeiGene

INDUSTRY

Sponsor Role: collaborator

Novartis

INDUSTRY

Sponsor Role: collaborator

Immix Biopharma, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

CIP Centro Integrado de Pesquisa / Hospital de Base / Fundação Faculdade de Medicina de São José do Rio Preto

São José do Rio Preto, São Paulo, Brazil

Site Status: RECRUITING

Instituto do Cancer do Estado de São Paulo (ICESP)

São Paulo, São Paulo, Brazil

Site Status: RECRUITING

Countries

Brazil

Central Contacts

Ilya Rachman, MD

Role: CONTACT

info@immixbio.com

8889581084

Facility Contacts

Daniel Araujo

Role: primary

Camila MV Moniz, MD

Role: primary

camila.venchiarutti@hc.fm.usp.br

551138932645

Other Identifiers

IMX-110-002

Identifier Type: -

Identifier Source: org_study_id